Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes: Implications for peptide-based immunotherapy

Journal of Immunology

Volumn 156, Issue 10, 1996, Pages 3882-3891

  Rivoltini, Licia ^a,b   Loftus, Douglas J ^a   Barracchini, Kathleen ^a   Arienti, Flavio ^b   Mazzocchi, Arabella ^b   Biddison, William E ^c   Salgaller, Michael L ^a   Appella, Ettore ^a   Parmiani, Giorgio ^b   Marincola, Francesco M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HLA A2 ANTIGEN; MELANOMA ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CAUCASIAN; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL;

ALLELES; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029968322     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. van der Bruggen, P., C Traversari, P. Chomez, C Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254:1643.
2. Kawakami, Y., S Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S L. Topalian, T. Miki, and S A. Rosenberg 1994 Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci USA 91.3515
3. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L Rivoltini, J. R. Yannelli, E Appella, and S. A Rosenberg. 1994. Identification of the immunodommant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp Med. 180: 347.
4. Kawakami, Y., S. Eliyahu, C. H. Delgado, P F. Robbins, K. Sakaguchi, E Appella, J. R. Yannelli, G. I. Adema, T. Miki, and S. A. Rosenberg. 1994 Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
5. Coulie, P G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E De Plaen, C. Lurquin, J. P Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
6. van der Bruggen, P., J Bastin, T. Gajewski, P. G. Coulie, P. Boel, C. De Smet, C. Traversari, A. Townsend, and T Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:3038.
7. Wolfel, T., A Van Pel, V. Brichard, I. Schneider, B. Seliger, K. H. Meyer zum Buschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759.
8. Wang, R. F., P. F. Robbins, Y Kawakami, X. Q. Kang, and S. A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J. Exp. Med. 181:1261; 1995]. J. Exp. Med. 181:799.
9. Kang, X , Y. Kawakami, M. el-Gamil, R. Wang, K. Sakaguchi, J R. Yannelli, E. Appella, S. A Rosenberg, and P. F. Robbins. 1995. Identification of a tyrosinase epitope recognized by HLA-A24-resnicted, tumor-infiltrating lymphocytes. J. Immunol 155.1343.
10. Robbins, P. F , M. el-Gamil, Y. F. Li, S. L. Topalian, L. Rivoltini, K. Sakaguchi, E. Appella, Y. Kawakami, and S. A. Rosenberg. 1995. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol 154:5944.
11. Kawakami, Y., S Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P F Robbins, A Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol 154:3961.
12. Wolfel, T., J. Schneider, K. H. Meyer zum Buschenfelde, H. G. Rammensee, O. Rotzschke, and K. Falk. 1994 Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2 1. Int. J Cancer 57:413.
13. Morioka, N., Y Kikumoto, D S. Hoon, D. L. Morton, and R. F. Irie. 1994 A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J. Immunol. 153:5650
14. Marincola, F. M., D. Venzon, D. White, J. T. Rubin, M. T Lotze, T. B. Simonis, J. Balkissoon, S. A. Rosenberg, and D. R. Parkinson. 1992. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy [published erratum appears in Cancer Res. 53:3846, 1993]. Cancer Res 52:6561.
15. Lee, T. D 1990, Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals. In The HLA System. J. Lee, ed Springer-Verlag, New York, p. 141.
16. Balch, C. M., A. N. Houghton, and L. J. Peters. 1993. Cutaneous Melanoma. In Cancer, Principles and Practice of Oncology, 4th Ed. V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds. J. B. Lippincott Co., Philadelphia, p 1612.
17. Fernandez-Vina, M. A., M Falco, Y. Sun, and P. Stastny 1992. DNA typing for HLA class I alleles I Subsets of HLA-A2 and of -A2&. Hum. Immunol. 33:163.
18. Krausa, P., M. Brywka, D. Savage, K. M. Hui, M. Bunce, J. L. Ngai, D. L. Teo, Y W. Ong, D. Barouch, C. E. Allsop, and et al. 1995. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 45:223.
19. U S. Bureau of the Census, ed. 1983. Ancestry of the population by state. In 1980 Census of Population. U S. Government Printing Office, Washington, DC, p. 1.
20. Lopez de Castro, J. A. 1989. HLA-B27 and HLA-A2 subtypes: structure, evolution and function. Immunol. Today 10:139
21. del Guercio, M F., J Sidney, G. Hermanson, C. Perez, H. M. Grey, R. T. Kubo, and A Sette. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154:685.
22. Tanigaki, N., D. Fruci, A. Chersi, G. Falasca, R. Tosi, and R. H. Butler 1994. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. Hum Immunol. 39:155.
23. Fruci, D., P. Rovero, G. Falasca, A. Chersi, R. Sorrentino, R Butler, N. Tanigaki, and R. Tosi. 1993. Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha chains. Hum. Immunol 38:187.
24. Rotzschke, O., K Falk, S. Stevanovic, G. Jung, and H. G. Rammensee. 1992. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur. J. Immunol 22:2453.
25. Ruppert, J . J. Sidney, E. Celis, R. T. Kubo, H. M. Grey, and A. Sette 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929
26. Hopkins, K. A., A van Leeuwen, G. N. Tardiff, and W. M. LeFor. 1990. Lymphotoxicity testing. In ASHI Laboratory Manual, 2nd Ed. A. A. Zachary and G. A Teresi, eds. American Society for Histocompatibility and Immunogenetics, Lenexa, KS, p. 195.
27. Marincola, F. M., P. Shamamian, R. B. Alexander, J. R. Gnarra, R. L. Turetskaya, S. A. Nedospasov, T. B. Simonis, J. K. Taubenberger, J. Yannelli, A. Mixon, et al. 1994. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines J. Immunol. 153.1225.
28. Browning, M. J., P. Krausa, A. Rowan, D. C. Bicknell, J. G. Bodmer, and W. F Bodmer 1993. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc. Natl. Acad. Sci. USA 90.2842.
29. Sadler, A M., F. Petronzelli, P. Krausa, S G. E. Marsh, M. G. Guttridge, M. J. Browning, and J. G. Bodmer. 1994. Low-resolution DNA typing for HLA-B using sequence-specific primers in allele- or group-specific ARMS/PCR. Tissue Antigens 44:148.
30. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P F Robbins, F. M. Marincola, M. Salgaller, J. R. Yannelli, E. Appella, and S A Rosenberg. 1995. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257
31. Salgaller, M. L., A. Afshar, F M. Marincola, L. Rivoltini, Y. Kawakami, and S A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55:4972.
32. Gotch, F., A McMichael, G. Smith, and B. Moss. 1987. Identification of viral molecules, recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 165:408
33. Moss, D. J., I. S. Misko, S. R. Burrows, K Burman, R. McCarthy, and T B Sculley 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719.
34. Milford, E. L., L. J. Kennedy, S. Y. Yang, B. Dupont, J-M Lalouel, and E J. Yanis. 1989. Serological characterization of the reference panel of B-lymphoblastoid cell lines for factors of the HLA system In Immunobiology of HLA. Vol. 1, Histocompatibility Testing 1987. B. Dupont, ed. Springer, New York, p. 19.
35. Rivoltini, L., K C. Baracchini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N P Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, and F. M Marincola. 1995. Quantitative correlation between HLA Class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res. 55:3149.
36. McMichael, A J., P. Parham, N. Rust, and F. Brodsky. 1980. A monoclonal antibody that recognizes an amigenic determinant shared by HLA A2 and B17. Hum. Immunol. 1:121.
37. Williams, A F. 1977. A monoclonal antibody recognizing HLA-A2 and A29 specificity. In Contemporary Topics in Molecular Immunology. R. R. Porter and G. L Ada, eds. Plenum Publishing Corp, New York, p. 83.
38. Russo, C., A. K. Ng, M. A. Pellegrino, and S. Ferrone. 1983 The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells Immunogenetics 18:23.
39. Kawakami, Y., S A. Rosenberg, and M. T. Lotze. 1988. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168:2183.
40. Sheil, J. M., M. J Bevan, and L. Lefrancois. 1987. Characterization of dual-reactive H-2Kb-restricted anti-vesicular stomatitis virus and alloreactive cytotoxic T cells. J. Immunol. 138:3654.
41. Smith, O. L , J. Z. Levin, P. Palese, and B. Moss 1987 Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses [published erratum appears in Virology 163:259, 1988]. Virology 160-336
42. Merchlinsky, M , and B. Moss. 1992 Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors [published erratum appears in Virology 192:717, 1993] Virology 190.522.
43. Moss, B. 1994 Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development. Dev. Biol. Stand. 82:55
44. O'Neil, B. H., Y. Kawakami, N. P. Restifo, J R. Bennink, J. W. Yewdell, and S. A. Rosenberg. 1993 Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA J. Immunol 151:1410.
45. Teng, J M., and K. T. Hogan. 1994. Both major and minor peptide-binding pockets in HLA-A2 influence the presentation of influenza virus matrix peptide to cytotoxic T lymphocytes. Mol. Immunol. 31:459.
46. Utz, U , S. Koenig, J. E. Coligan, and W E. Biddison. 1992. Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the- HLA-A2.1 molecule. J. Immunol. 149:214.
47. Matsui, M., R. J. Moots, R. J. Warburton, A L. Peace-Brewer, L G Tussey, D. G. Quinn, A. J. McMichael, and J. A. Frelinger. 1995. Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. J. Immunol. 154.1088.
48. Sette, A., J. Sidney, M. F. del Guercio, S. Southwood, J. Ruppert, C Dahlberg, H. M. Grey, and R. T. Kubo 1994. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays Mol Immunol. 31:813.
49. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L Darrow, J, Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines Science 264.716.
50. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B Lethe, P Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 178-489.
51. Appella, E., D. J. Loftus, K. Sakaguchi, A Sette, and E. Celis 1995 Synthetic antigenic peptides as a new strategy for immunotherapy of cancer Biol. Peptides, Proteins Nucleic Acids 1:177
52. Celis, E , V Tsai, C. Crimi, R. DeMars, P. A Wentworth, R W Chesnut, H. M Grey, A Sette, and H. M Serra 1994 Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad Sci USA 91:2105.
53. Marincola, F M., P. Shamamian, L Rivoltini, M L Salgaller, I. Reid, N P Restifo, T. B. Simonis, D. Venzon, D. E. White, and D R Parkinson 1996 HLA associations in the anti-tumor response against malignant melanoma J. Immunother. 18.242.
54. Vitiello, A., G. Ishioka, H. M Grey, R Rose, P Farness, R LaFond, L Yuan, F. V. Chisari, J. Furze, R Bartholomeuz, et al. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection I. Induction of a primary cytotoxic T lymphocyte response in humans J Clin Invest 95.341
55. Vitiello, A., D. Marchesini, J. Furze, L A. Sherman, and R W Chesnut 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med. 173.1007
56. Sette, A , A. Vittello, B Reherman, P Fowler, R Nayersina, W M. Kast, C. J Melief, C Oseroff, L Yuan, J Ruppert and et al. 1994. The relationship between class I binding affinity and immunogemcity of potential cytototic T cell epitopes. J Immunol 153.5586.
57. Carreno, B M , S. Koenig, J. E. Coligan, and W. E Biddison. 1992 The peptide binding specificity of HLA class I molecules is largely allele-specific and non-overlapping. Mol. Immunol 29:1131.
58. McMichael, A J., F M. Gotch, J. Santos-Aguado, and J. L. Strominger. 1988. Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes Proc. Natl. Acad. Sci. USA 85.9194.
59. Nikolic-Zugic, J , and F. R. Carbone. 1990. The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the Kb-restricted ovalbumin determinant Eur J. Immunol. 20:2431.
60. Madden, D R., D. N. Garboczi, and D C Wiley. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2 [published erratum appears in Cell 76:410, 1994]. Cell 75.691
61. Sudo, T , N Kamikawaji, A Kimura, Y Date, C J. Savoie, H. Nakashima, E Furuichi, S Kuhara, and T Sasazuki 1995. Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J. Immunol 155:4749.